A University of Cincinnati expert on posttraumatic stress disorder (PTSD) will play a leading role in a 17-site, $9 million study that will compare the two leading evidence-based treatments for PTSD.
University of Cincinnati (UC) Cancer Institute researchers are testing the ability of a novel lung cancer vaccine to increase the body’s natural immune defense system against cancerous tumors.
UC is known for excellence in research, and George Deepe, MD, has played a part in that reputation with his contributions to infectious diseases research.
For more than 15 years, deep brain stimulation (DBS) surgery has been an important treatment option for people with Parkinson’s disease, a disorder of the nervous system caused by a lack of dopamine in the brain.
A new oral vaccine that produces a novel two-pronged immune system attack on cancer cells could be effective in preventing breast cancer recurrence, according to findings from a collaborative research team from the University of Cincinnati (UC) Cancer Institute and the National Institutes of Health (NIH).
The University of Cincinnati will lead a $5.2 million national trial studying removal of both corticosteroids and common immunosuppression treatments from the post-transplant drug regimen for kidney transplant patients.
“I love the intellectual challenges of medicine and the fact that solutions lead to improved health care.”